We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Groundbreaking Blood Test Detects Tumors Early in High-Risk Families

By LabMedica International staff writers
Posted on 25 Oct 2023
Print article
Image: A simple blood draw may improve early diagnosis and reduce invasive tests in people with LFS (Photo courtesy of 123RF)
Image: A simple blood draw may improve early diagnosis and reduce invasive tests in people with LFS (Photo courtesy of 123RF)

Li-Fraumeni syndrome (LFS) is a hereditary genetic disorder that comes with an almost certain risk of developing cancer at some point in life. The condition is due to mutations in the TP53 gene, which is responsible for making a protein that acts as a sort of "genome protector" by inhibiting tumor development. People with LFS are susceptible to developing a variety of cancers, affecting organs like the breast, soft tissues, and brain, among others. For kids who have LFS, frequent visits to healthcare facilities for yearly brain and full-body MRIs, along with regular blood draws, ultrasounds, and physical check-ups, are crucial for early cancer detection. However, these frequent tests can be both stressful for families and taxing on the healthcare system. Now, a simple blood test can accurately identify when and sometimes even where cancer is developing.

Researchers from The Hospital for Sick Children (Toronto, ON, Canada) have developed a more effective way to detect early stages of cancer in LFS patients, using a method called "liquid biopsy." This method examines DNA fragments in blood samples that are shed by cancer cells. The team examined 170 blood samples collected from 82 people with LFS over multiple years. Their results revealed that early signs of leukemia were evident in a patient several months before any visible tumor or symptoms appeared. This provides a proof-of-principle framework that could support the detection of cancers in their early stages in people with LFS and possibly others.

The findings of this study could eventually eliminate the need for the myriad of tests currently required, while simultaneously increasing the accuracy and specificity of cancer diagnoses. In the upcoming months, a clinical trial will be carried out to further examine this new approach. The trial aims to discover cancers earlier and will involve individuals who have different kinds of cancer-prone genetic syndromes, including LFS, Lynch syndrome, neurofibromatosis, and hereditary breast and ovarian cancer.

“These promising findings can be extended to all hereditary cancer syndromes to help improve the accuracy of cancer detection, especially for common tumour types, utilizing several types of analyses that leverage different biological measurements,” said Dr. David Malkin, Senior Staff Oncologist and Senior Scientist who led the study at SickKids.

Related Links:
The Hospital for Sick Children 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.